Comparative efficacy of antiangiogenic treatment for newly diagnosed glioblastoma: A protocol for systematic review and network meta-analysis

BACKGROUND: Glioblastoma is the most common malignant primary brain tumor which has highly expressed vascular endothelial growth factor. To date, various antiangiogenic drugs have been investigated in clinical trials but with no overall conclusion, especially for newly diagnosed glioblastoma (nGBM)....

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Runting, Li, Chao, Cai, Zhaolun, Li, Lianwang, Wei, Liudong, Qian, Zenghui, Zhou, Dabiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220263/
https://www.ncbi.nlm.nih.gov/pubmed/32384458
http://dx.doi.org/10.1097/MD.0000000000020011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220263/
https://www.ncbi.nlm.nih.gov/pubmed/32384458
http://dx.doi.org/10.1097/MD.0000000000020011

Ejemplares similares